73631-29-5

Basic information

• Product Name: 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine
• Synonyms: 2,6-pyrazinediamine, 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-; 3-(3-Amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine
• CAS NO: 73631-29-5
• Molecular Formula: C₆H₆ClN₇O
• Molecular Weight: 227.6111
• Mol File: 73631-29-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 583.9°C at 760 mmHg
• Flash Point: 306.9°C
• Density: 1.761g/cm³
• Vapor Pressure: 1.28E-13mmHg at 25°C
• Refractive Index: 1.759
• CAS DataBase Reference: 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine(73631-29-5)
• EPA Substance Registry System: 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloropyrazine-2,6-diamine(73631-29-5)

Safety Data

• Hazardous Substances Data: 73631-29-5(Hazardous Substances Data)

Upstream product

• 1458-01-1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester 
• 17231-59-3 3,5-diamino-6-chloro-2-pyrazinecarbonitrile 
• 73631-28-4 3,5-Diamino-6-chloro-pyrazine-2-carboximidic acid ethyl ester; hydrochloride 
• 32205-65-5 3,5-diamino-6-chloro-N-<(hydroxyimino)aminomethylene>pyrazine-2-carboxamide 
• 73631-17-1 N^α-cyano-3,5-diamino-6-chloropyrazine-2-carboxamide hydrochloride 

Relevant articles and documents

The colour reaction of amiloride hydrochloride ph. eur.

The reaction of amiloride hydrochloride (1.HCI) with bromine in alkaline solution generated a yellow-brown dehydrogenation product, which turned out as 3-(3-amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazinediamine (2). The structure was deduced from the MS and the NMR spectra of 2 with the help of comparisons with corresponding spectra of amiloride (1) and reference substances 3 - 5. The agreement of all relevant data of the product and of authentical oxadiazolylpyrazine 2 as well as the accomplished X-ray analysis confirmed the postulated structure. The mechanism of the formation of 2 is also discussed.

Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)

A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum

Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic

Novel pyrazinyl -1,2,4-oxadiazoles of the formulas: STR1 are useful in treating edema and hypertension, and particularly may be combined with kaliuretic diuretics such as hydrochlorothiazide and indacrinone.